Israeli Drug Development Companies Are Poised for 505(b)(2) Development Process, Camargo Expert Says
December 17th 2013Many Israeli pharmaceutical executives recently learned that the 505(b)(2) development process is an important tool that can significantly reduce costs and shorten the timeline for approval of new drugs, adding substantially to ROI.